Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome.
Hande ErmanEngin BeydoganSeher Irem CetinBanu BoyukPublished in: Mediators of inflammation (2020)
Serum endocan concentrations are low in patients with NAFLD, and the optimum cutoff point is 122.583 pg/mL. HSI and FLI were higher in patients with NAFLD; however, there was no correlation with serum endocan.